Prof. dr. Damjana Drobne participated in the official visit of the President of the Republic of Slovenia Borut Pahor to Iran for the opening of the Slovenian embassy in Teheran. During the visit, the Memorandum of Understanding on Scientific Cooperation between Iran Nanotechnology Initiative Council (INIC), Tehran, the Islamic Republic of Iran, and the Slovenian Research Agency (ARRS), Ljubljana, the Republic of Slovenia, was signed as a basis for future cooperation in nanotechnology and nano-sciences. She was invade to visit together with the director of ARRS and some others Iran Nanotechnology Initiative Council (INIC) and discussed future cooperation.http://www.nhz.si/index.php/english/news/we-participated-official-visit-president-republic-slovenia-iraninitiative-council/
F.35 Other
As a member of EU delegation for nanosafety prof. dr. DDrobne attendee the first Asia-Europe summit on nano-safety and nano-product held at Tehran University of Medical Sciences on November 28, 2017. At the meeting, Iranian representatives proposed a direct dialogue and mutual collaboration between Europe and Asia to develop the required scientific knowledge, tools and standards for evaluation nano-products safety via a harmonized legislations and certification methodology. The aim of this strategy is to guarantee the safety and health of nano-products and build the consumers’ confidence and trust http://en.nano.ir/news.php?id=169 .
D.08 Management and development of research activities
Prof. D.Drobne is active in Slovenian Innovation Hub (www.sis-egiz.eu). From January 2017 on, she is an assistant director and also leading strategic pillar Active and healthy aging within Slovenian Strategic Research And Innovation Partnerships (SRIP) - Health – medicine. From June 2017 she is co-coordinator of Slovenian nano-technological hub.
D.08 Management and development of research activities
Prof. dr. Drobne has proposed and is leading a Task Force for TiO2 to adequately and accurate cover the scientific findings regarding TiO2 and TiO2 nano safety and to provide independent and transparent scientific opinion and advice to stakeholders. The selection criteria for available studies will be applied to find the best available in vivo and in vitro evidence; the later might serve to understand underlying mechanisms. The deliverables will include a report to be published in a scientific journal on recent evidence on genotoxicity, mutagenicity and carcinogenicityof TiO2 considering inhalation, as well as oral and dermal route of exposure. Information will be collected from NSC/ EU funded projects as well as from recent publications in the scientific literature and recent publically available reports. An opinion on the CLH for TiO2 dossier to ECHA, EFSA, NIA, CEPE, TDMA will also be delivered and (generic) guidelines for nano-safty state of the art to be used by regulators (REACH and CLH regulation). The Task Force will also try to propose a scheme for communicating scientific evidence regarding nanomaterial safety findings in the most efficient and transparent way.
D.01 Chairing over/coordinating (international and national) projects